# natureresearch

Corresponding author(s):	Xosé R. Bustelo
Last updated by author(s):	Sep 14, 2020

# **Reporting Summary**

**Statistics** 

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see <u>Authors & Referees</u> and the <u>Editorial Policy Checklist</u>.

For all statistical analyse	es, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.				
n/a Confirmed					
The exact sam	ple size $(n)$ for each experimental group/condition, given as a discrete number and unit of measurement				
A statement o	A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly				
The statistical Only common to	The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.				
A description of all covariates tested					
🔲 🗴 A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons					
A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)					
For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i> ) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted Give <i>P</i> values as exact values whenever suitable.					
For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings					
For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes					
Estimates of effect sizes (e.g. Cohen's <i>d</i> , Pearson's <i>r</i> ), indicating how they were calculated					
	Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.				
Software and code					
Policy information abou	ut <u>availability of computer code</u>				
Data collection	No software was used for data collection.				
Data analysis	GraphPad Prism software (version 6.0 and 8.3.1). LAS AF software (version 2.6.0.72266, Leica). StepOne software v2.1 (Applied Biosystems). ImageJ software (version 2.0.0-rc-69/1.52p; National Institutes of Health, Bethesda, MD).				
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.					
Data					
Policy information abou	ut <u>availability of data</u>				
- Accession codes, uni - A list of figures that l	nclude a <u>data availability statement</u> . This statement should provide the following information, where applicable: que identifiers, or web links for publicly available datasets have associated raw data restrictions on data availability				
The datasets generated d	uring the current study are available from the corresponding author upon reasonable request.				
Field-speci	fic reporting				
Please select the one be	elow that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.				
X Life sciences	Behavioural & social sciences Ecological, evolutionary & environmental sciences				

# Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size

No statistical methods were used to determine sample size. In general, at least three independent replicates were performed in all experiments. For experiments subjected to higher variability, such as metabolic analyses, a larger number of animals was used. When possible, we have aimed for the replication of the animal experiments in at least two different cohorts. The sample size used for each experiment is indicated at the corresponding figure legend in the manuscript.

Data exclusions

Only significant outliers were excluded from the analysis. In figure 7c, one Vav2 L33A/L332A animal was excluded (0 min time-point). In figure S16c, one CD-fed WT was excluded in the 0 min time-point. In figure 7k, the 120 min time-point of a WT animal was excluded (lower than the 90 min time-point for the same mouse and significantly lower than the other animals). In figure 1a, one WT mice was excluded due to its low lean mass and abnormal metabolic parameters. In figure S11c, a 2-month-old Vav2 L332A/L332A animal was excluded due to its high adiposity content. In Fig. 8A, a WT animal had to be excluded from the final analysis and sacrificed due to health problems.

Replication

The number of independent replicates for each experiment is indicated at the corresponding figure legend in the manuscript. In general, at least three independent replicates were performed.

Randomization

In all cell and animal studies, groups were allocated randomly. Age and gender-matched animals were used in all the experiments.

Blinding

For all animal studies, the investigators were blind to group allocation. Blinding was not applicable to the rest of experiments.

## Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materiais & experimental systems		IVIE	Methods	
n/a	Involved in the study	n/a	Involved in the study	
	<b>x</b> Antibodies	x	ChIP-seq	
	<b>▼</b> Eukaryotic cell lines		<b>✗</b> Flow cytometry	
x	Palaeontology	x	MRI-based neuroimaging	
	🗶 Animals and other organisms			
x	Human research participants			

#### **Antibodies**

Antibodies used

X Clinical data

The antibodies used are described in the Methods section of the manuscript.

- Antibodies used in Western Bot: phospho-Akt (Thr308) (dilution 1:1000; Cat. #4056, Cell Signaling Technologies), Akt (dilution 1:1000; Cat. #2920, Cell Signaling Technologies), phospho-GSK3α/β (dilution 1:1000; Cat. #9327, Cell Signaling Technologies), GSK3α/β (dilution 1:1000; Cat. #5676, Cell Signaling Technologies), phospho-S6K (Thr389) (dilution 1:1000; Cat. #9215, Cell Signaling Technologies), phospho-ERK1/2 (Thr202/Tyr204) (dilution 1:1000; Cat. #4370, Cell Signaling Technologies), tubulin (dilution 1:2000; Cat. #CP06, Calbiochem), MHCII (dilution 1:2000; Cat. #M4276; Sigma), S6K (dilution 1:1000; Cat. #sc-230, Santa Cruz Biotechnologies), HA (dilution 1:1000; Cat. #3724, Cell Signaling Technologies), phospho-Tyr (for detecting phospho-IRS1; 1:1000 dilution, Cat. #sc-7020, Santa Cruz Biotechnologies), IRS1 (dilution 1:1000; Cat. #05-1085, Millipore), Rac1 (dilution 1:1000; Cat. #ARC03, Cytoskeleton), GFP (dilution 1:200; Cat. #902601, BioLegend), and Ucp1 (dilution 1:500; Cat. #sc-293418, Santa Cruz Biotechnologies). The polyclonal rabbit antibody to Vav2 (dilution 1:1000) was homemade using as epitope the acidic region of this protein.

- Antibodies used in immunofluorescence: antibody to the Myc epitope (Cat. #M5546, Sigma-Aldrich; 1:1000 dilution), and MHCII (1:700, Cat. #M4276; Sigma-Aldrich).

Validation

Commercially available antibodies (see above) have been validated by the manufacturer for the application (immunoblot, immunoprecipitation or immunocytochemistry) and species. This information is available at each manufacturer's website and can be obtained through the catalog numbers indicated above. The homemade Vav2 antibody has been validated by us in overexpression, knockdown and knockout experiments.

#### Eukaryotic cell lines

Policy information about cell lines

Cell line source(s)

HEK293 (ATCC) and C2C12 (ATCC, obtained from Pura Muñoz-Canoves)

Authentication ATCC cell lines are authenticated by the manufacturer. No additional authetication procedures were performed.

Mycoplasma contamination All cell lines tested negative for mycoplasma contamination.

Commonly misidentified lines (See <u>ICLAC</u> register)

No commonly misidentified cell lines were used in this study.

#### Animals and other organisms

Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research

Laboratory animals

Mus musculus. C57BL/6 and C57BL/10 backgrounds, both females and males (insulin and IGF infusion experiments) or males only

(rest) were used with ages ranging between 2 and 12 months. The genotype (Vav2Onc/Onc, Vav2—/—, Vav2L332A/L332A or their correspondent WT) and age of the animals used in each experiment is detailed in the figure legends and the Methods section of the manuscript. Animals were kept in ventilated rooms in pathogen—free facilities under controlled temperature (23°C), humidity

(50%), and illumination (12–hour–light/12–hour–dark cycle) conditions.

Wild animals No wild animals were used in this study.

Field-collected samples No field-collected samples were used in this study.

Ethics oversight Approved by the Bioethics Committees of the Universities of Salamanca, Santiago de Compostela and Geneva, as approppiate.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

#### Flow Cytometry

### Plots

Confirm that:

- The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
- The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
- All plots are contour plots with outliers or pseudocolor plots.
- 🗶 A numerical value for number of cells or percentage (with statistics) is provided.

#### Methodology

Sample preparation The protocol is detailed in the Methods section of the manuscript.

Instrument BD FACS Aria II (BD Biosciences)

Software FlowJo 8.7.3

Cell population abundance The abundance of the stem cell population in the Sca1-/CD45- population was around 5%.

Gating strategy After a first gating using FSC-A/SSC-A, only the Sca1-/CD45- population was gated. The CD34+/Integrin alpha7+ population was

considered the satellite cell population.

x Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.